Qiming Wang

发表论文 157 篇 · 总被引 5965 次 · h-index 33

代表论文

• AENEAS: A Randomized Phase III Trial of Aumolertinib Versus Gefitinib as First-Line Therapy for Locally Advanced or MetastaticNon–Small-Cell Lung Cancer With EGFR Exon 19 Deletion or L858R Mutations (2022 · Journal of Clinical Oncology · 被引 247)
• Aberrant m5C hypermethylation mediates intrinsic resistance to gefitinib through NSUN2/YBX1/QSOX1 axis in EGFR-mutant non-small-cell lung cancer (2023 · Molecular Cancer · 被引 186)
• Sintilimab plus chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer with disease progression after EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): second interim analysis from a double-blind, randomised, placebo-controlled, phase 3 trial. (2023 · The Lancet Respiratory Medicine · 被引 138)
• Camrelizumab Plus Carboplatin and Pemetrexed as First-line Treatment for Advanced Non-squamous NSCLC: Extended Follow-up of CameL Phase 3 Trial. (2023 · Journal of Thoracic Oncology · 被引 66)
• Chinese expert consensus on the diagnosis and treatment of thymic epithelial tumors (2023 · Thoracic Cancer · 被引 30)
• ARTEMIS-001: Phase 1 study of HS-20093, a B7-H3–targeting antibody-drug conjugate, in patients with advanced solid tumor. (2023 · Journal of Clinical Oncology · 被引 26)